Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.
Drug Saf
; 44(5): 515-530, 2021 05.
Article
in En
| MEDLINE
| ID: mdl-33527177
Full text:
1
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Antirheumatic Agents
/
Janus Kinase Inhibitors
/
Herpes Zoster
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Year:
2021
Type:
Article